# CYP2C19 clopidogrel efficacy validation (outcome-linked)

Generated: 2026-01-04T11:06:49Z

Source: PMID 40944685 (PMC 12673833), Table 4

## Outcome association
- Extensive metabolizer: 5/106 (4.7%)
- Poor/Intermediate: 21/104 (20.2%)
- Risk ratio (PM/IM vs EM): 4.28
- Fisher two-sided p: 0.000673
- Reported multivariate HR (table): 5.26 (1.87-14.56)

## System recommendation examples (CYP2C19 â†’ clopidogrel)
- *1/*1 (Normal Metabolizer): No clopidogrel adjustment returned
- *1/*2 (Intermediate Metabolizer): [{'drug': 'Clopidogrel', 'adjustment': 'Consider alternative P2Y12 inhibitor (prasugrel or ticagrelor) or alternative strategy per guideline context', 'rationale': 'Intermediate metabolizers have reduced clopidogrel activation and can have higher ischemic event risk depending on clinical setting'}]
- *2/*2 (Poor Metabolizer): [{'drug': 'Clopidogrel', 'adjustment': 'Use alternative P2Y12 inhibitor (prasugrel or ticagrelor)', 'rationale': 'Poor metabolizers have reduced clopidogrel activation'}]
